LinkOPH

Acucela has entered into an exclusive licensing agreement with the University of Manchester to develop and commercialize the university’s human rhodopsin-based optogenetic gene therapy to treat retinitis pigmentosa and related conditions, according to a company press release. “We are extremely excited to enter into this collaboration with the University of Manchester and to begin the important development work needed to unlock the potential of optogenetic gene therapy to improve visual function in patients who have lost much of their vision as well as their hope,” Ryo Kubota, MD, PhD, chairman, (Read more...)

Welcome to another edition of CEDARS/ASPENS Debates. CEDARS/ASPENS is a joint society of cornea, cataract and refractive surgery specialists, here to discuss some of the latest hot topics in ophthalmology.Dry eye disease is one of the most frequently seen problems in the eye care professional’s office. Cyclosporine drops have become the mainstay of treatment of this condition. Some physicians have noted difficulty with the initiation of cyclosporine due to the delay in onset and the subjective irritation some patients note upon instillation. This month, Jonathan D. Solomon, MD, and Cynthia (Read more...)

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aura Biosciences announced today that Elisabet de los Pinos, founder and CEO, will present a company overview at the 15th Annual Needham Healthcare Conference in New York, N.Y.

Read more →